#CRAVAT Report
#Created at Monday 12/20/2021 12:00:14
#Report level: variant
#
Variant Annotation																OncoKB												Original Input			
UID	Chrom	Position	Ref Base	Alt Base	Note	Coding	Gene	Transcript	Sequence Ontology	cDNA change	Protein Change	All Mappings	Sample Count	Samples	Tags	Oncogenic	Known Effect	Hotspot	Highest Sensitive Level	Highest Resistance Level	Highest Dx Level	Highest Px Level	PubMed	Gene Summary	Variant Summary	Tumor Summary	All Annotations	Chrom	Pos	Reference allele	Alternate allele
1	chr10	2987654	T	A									1	s1			Unknown											chr10	2987654	T	A
2	chr10	43077259	A	T		Yes	RET	ENST00000355710.8	start_lost	c.1A>T	p.Met1?	ENST00000340058.6:RET:P07949:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000355710.8:RET:P07949:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000615310.4:RET::missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000671844.1:RET::missense_variant,start_lost,NMD_transcript_variant:p.Met1?:c.1A>T; ENST00000672389.1:RET::missense_variant,start_lost,NMD_transcript_variant:p.Met1?:c.1A>T	1	s2			Unknown	False						RET, a receptor tyrosine kinase, is altered by mutation in medullary thyroid cancers and by chromosomal rearrangement in lung cancers, papillary thyroid cancers, and rarely, other solid tumors.	The biologic significance of the RET M1? mutation is unknown.			chr10	43077259	A	T
3	chr10	8055656	A	T		Yes	GATA3	ENST00000379328.9	start_lost	c.1A>T	p.Met1?	ENST00000346208.4:GATA3:P23771:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000379328.9:GATA3:P23771:missense_variant,start_lost:p.Met1?:c.1A>T	1	s3		Likely Oncogenic	Likely Loss-of-function	False			3		23426732; 18242514; 26637396; 27588951; 24758297	GATA3, a transcription factor, is altered by mutation or amplification in various cancers, most frequently in breast cancer.	The GATA3 M1? mutation is likely oncogenic.		[[{"diagnostic_data": ["3", "T-Lymphoblastic Leukemia/Lymphoma", "LIQUID", ["22237106"]]}]]	chr10	8055656	A	T
4	chr10	87864470	A	T		Yes	PTEN	ENST00000371953.8	start_lost	c.1A>T	p.Met1?	ENST00000371953.8:PTEN:P60484:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000445946.4:KLLN:B2CW77:2kb_upstream_variant::c.-1983T>A; ENST00000487939.1:PTEN::processed_transcript::; ENST00000618586.1:PTEN::2kb_upstream_variant,processed_transcript::	1	s4		Likely Oncogenic	Likely Loss-of-function	False			3		17218262; 11237521	PTEN, a lipid and protein phosphatase, is one of the most frequently mutated genes in cancer.	The PTEN M1? mutation is likely oncogenic.		[[{"diagnostic_data": ["3", "T-Lymphoblastic Leukemia/Lymphoma", "LIQUID", ["19458356", "22491738", "19340001"]]}]]	chr10	87864470	A	T
5	chr11	113789394	G	A									1	s3			Unknown	False										chr11	113789394	G	A
6	chr1	111762684	G	A		Yes	DDX20	ENST00000369702.5	missense_variant	c.1112G>A	p.Arg371His	ENST00000369702.5:DDX20:Q9UHI6:missense_variant:p.Arg371His:c.1112G>A; ENST00000475700.1:DDX20::5_prime_UTR_variant::c.-188G>A; ENST00000533164.5:DDX20:Q9UHI6:NMD_transcript_variant,3_prime_UTR_variant::c.*526G>A	1	s4			Unknown											chr1	111762684	G	A
7	chr11	119206418	A	T		Yes	CBL	ENST00000264033.6	start_lost	c.1A>T	p.Met1?	ENST00000264033.6:CBL:P22681:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000634586.1:CBL::missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000634840.1:CBL::missense_variant,start_lost:p.Met1?:c.1A>T	1	s0		Likely Oncogenic	Likely Loss-of-function	False			2	1	22315494; 20508043; 20694012	CBL, a tumor suppressor and ubiquitin ligase, is inactivated by mutation or deletion in various cancer types including myeloid malignancies.	The CBL M1? mutation is likely oncogenic.		[[{"diagnostic_data": ["2", "Myelodysplastic/Myeloproliferative Neoplasms", "LIQUID", ["22919025", "23690417"]]}], [{"diagnostic_data": ["2", "Myelodysplastic/Myeloproliferative Neoplasms", "LIQUID", ["23832011", "25691160", "20543203"]]}], [{"diagnostic_data": ["2", "Myelodysplastic Syndromes", "LIQUID", ["19387008", "24030381", "21714648", "25465125", "24220272"]]}], [{"prognostic_data": ["1", "Myelodysplastic Syndromes", "LIQUID", "Myeloid", ["21714648", "24220272"]]}]]	chr11	119206418	A	T
8	chr1	11847684	T	A		Yes	NPPA	ENST00000376480.7	start_lost	c.1A>T	p.Met1?	ENST00000376476.1:NPPA::intron_variant::c.-27-245A>T; ENST00000376480.7:NPPA:P01160:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000400892.3:CLCN6::NMD_transcript_variant,3_prime_UTR_variant::c.*2069T>A; ENST00000610706.1:NPPA::missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000617059.1:AL021155.2::2kb_downstream_variant,misc_RNA::; ENST00000618496.1:AL021155.4::2kb_downstream_variant,misc_RNA::	1	s0			Unknown											chr1	11847684	T	A
9	chr1	12000	A	T									1	s1			Unknown											chr1	12000	A	T
10	chr1	120069406	T	A		Yes	NOTCH2	ENST00000256646.7	start_lost	c.1A>T	p.Met1?	ENST00000256646.7:NOTCH2:Q04721:missense_variant,start_lost:p.Met1?:c.1A>T; ENST00000652302.1:NOTCH2::missense_variant,start_lost:p.Met1?:c.1A>T	1	s2		Likely Oncogenic	Likely Loss-of-function	False			3		22006338	NOTCH2 encodes a transmembrane receptor that regulates many aspects of development by affecting cell-fate determination.	The NOTCH2 M1? mutation is likely oncogenic.		[[{"diagnostic_data": ["3", "Mature B-Cell Neoplasms", "LIQUID", ["24296945", "22891276", "25779943", "22891273"]]}]]	chr1	120069406	T	A
11	chr1	12644547	A	T		Yes	AADACL4	ENST00000376221.1	start_lost	c.1A>T	p.Met1?	ENST00000376221.1:AADACL4:Q5VUY2:missense_variant,start_lost:p.Met1?:c.1A>T	1	s3			Unknown											chr1	12644547	A	T
12	chr1	12666560	G	A		Yes	AADACL4	ENST00000376221.1	missense_variant	c.1049G>A	p.Arg350His	ENST00000376221.1:AADACL4:Q5VUY2:missense_variant:p.Arg350His:c.1049G>A	1	s4			Unknown											chr1	12666560	G	A
13	chr5	112838363	A	C		Yes	APC	ENST00000257430.9	missense_variant	c.2769A>C	p.Arg923Ser	ENST00000257430.9:APC:P25054:missense_variant:p.Arg923Ser:c.2769A>C; ENST00000508376.6:APC:P25054:missense_variant:p.Arg923Ser:c.2769A>C; ENST00000508624.5:APC::NMD_transcript_variant,3_prime_UTR_variant::c.*2091A>C	1	s1			Unknown	False						APC, a tumor suppressor involved in WNT signaling, is recurrently altered in colorectal cancer.	The biologic significance of the APC R923S mutation is unknown.			chr5	112838363	A	C
14	chr9	130872896	C	T		Yes	ABL1	ENST00000318560.6	missense_variant	c.944C>T	p.Thr315Ile	ENST00000318560.6:ABL1:P00519:missense_variant:p.Thr315Ile:c.944C>T; ENST00000372348.7:ABL1:P00519:missense_variant:p.Thr334Ile:c.1001C>T	1	s0		Resistance	Likely Gain-of-function	False	1	1			18794843; 11423618	ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	The ABL1 T315I is a known resistance mutation.		[[{"treatment_data": [["C62035"], ["Imatinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 3, "B-Lymphoblastic Leukemia/Lymphoma", "Lymphoid", "LIQUID"]}], [{"treatment_data": [["C62035"], ["Imatinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 4, "Chronic Myelogenous Leukemia", "Myeloid", "LIQUID"]}], [{"treatment_data": [["C38713"], ["Dasatinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 3, "B-Lymphoblastic Leukemia/Lymphoma", "Lymphoid", "LIQUID"]}], [{"treatment_data": [["C38713"], ["Dasatinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 4, "Chronic Myelogenous Leukemia", "Myeloid", "LIQUID"]}], [{"treatment_data": [["C48375"], ["Nilotinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 3, "B-Lymphoblastic Leukemia/Lymphoma", "Lymphoid", "LIQUID"]}], [{"treatment_data": [["C48375"], ["Nilotinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 4, "Chronic Myelogenous Leukemia", "Myeloid", "LIQUID"]}], [{"treatment_data": [["C60809"], ["Bosutinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 3, "B-Lymphoblastic Leukemia/Lymphoma", "Lymphoid", "LIQUID"]}], [{"treatment_data": [["C60809"], ["Bosutinib"], [], ["17768119", "18403620", "19075254", "17339191", "21562040"], 4, "Chronic Myelogenous Leukemia", "Myeloid", "LIQUID"]}], [{"treatment_data": [["C95777"], ["Ponatinib"], [], ["24180494", "23190221", "29567798"], 3, "B-Lymphoblastic Leukemia/Lymphoma", "Lymphoid", "LIQUID"]}], [{"treatment_data": [["C95777"], ["Ponatinib"], [], ["24180494", "23190221", "19878872"], 4, "Chronic Myelogenous Leukemia", "Myeloid", "LIQUID"]}], [{"treatment_data": [["C114494"], ["Asciminib"], [], [], 4, "Chronic Myelogenous Leukemia", "Myeloid", "LIQUID"]}]]	chr9	130872896	C	T
15	chr17	7675153	GGGCGGGGGT	-		Yes	TP53	ENST00000269305.8	frameshift_truncation	c.450_459del	p.Pro151AlafsTer16	ENST00000269305.8:TP53:P04637:frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000359597.8:TP53::frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000413465.6:TP53::frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000420246.6:TP53:P04637:frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000445888.6:TP53:P04637:frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000455263.6:TP53:P04637:frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000504290.5:TP53:P04637:frameshift_truncation:p.Pro19AlafsTer16:c.54_63del; ENST00000504937.5:TP53:P04637:frameshift_truncation:p.Pro19AlafsTer16:c.54_63del; ENST00000510385.5:TP53:P04637:frameshift_truncation:p.Pro19AlafsTer16:c.54_63del; ENST00000574684.1:TP53::2kb_upstream_variant,processed_transcript::; ENST00000610292.4:TP53:P04637:frameshift_truncation:p.Pro112AlafsTer16:c.333_342del; ENST00000610538.4:TP53:P04637:frameshift_truncation:p.Pro112AlafsTer16:c.333_342del; ENST00000610623.4:TP53::5_prime_UTR_variant::c.-28_-19del; ENST00000615910.4:TP53::frameshift_truncation:p.Pro140AlafsTer16:c.417_426del; ENST00000617185.4:TP53:P04637:frameshift_truncation:p.Pro151AlafsTer16:c.450_459del; ENST00000618944.4:TP53::5_prime_UTR_variant::c.-28_-19del; ENST00000619186.4:TP53::5_prime_UTR_variant::c.-28_-19del; ENST00000619485.4:TP53:P04637:frameshift_truncation:p.Pro112AlafsTer16:c.333_342del; ENST00000620739.4:TP53:P04637:frameshift_truncation:p.Pro112AlafsTer16:c.333_342del; ENST00000622645.4:TP53:P04637:frameshift_truncation:p.Pro112AlafsTer16:c.333_342del; ENST00000635293.1:TP53::frameshift_truncation,NMD_transcript_variant:p.Pro112AlafsTer16:c.333_342del	1	s1		Likely Oncogenic	Likely Loss-of-function	False				1	19336573; 27759562; 16007150; 11753428; 11900253; 21467160	TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.	The TP53 P151Afs*16 mutation is likely oncogenic.		[[{"prognostic_data": ["1", "Leukemia", "LIQUID", "Myeloid", ["25412851", "25860933"]]}], [{"prognostic_data": ["1", "Leukemia", "LIQUID", "Myeloid", ["22186996", "18596741"]]}], [{"prognostic_data": ["1", "Leukemia", "LIQUID", "Myeloid", ["25412846", "25952993"]]}], [{"prognostic_data": ["1", "Mature B-Cell Neoplasms", "LIQUID", "Lymphoid", ["23243274", "24004666", "20697090", "19188171", "24652989"]]}], [{"prognostic_data": ["1", "Myelodysplastic Syndromes", "LIQUID", "Myeloid", ["21714648", "25092778", "24220272"]]}], [{"prognostic_data": ["1", "Myeloproliferative Neoplasms", "LIQUID", "Myeloid", ["24478400", "29296692", "22887079"]]}], [{"prognostic_data": ["1", "Myeloproliferative Neoplasms", "LIQUID", "Myeloid", ["25516983", "22052707", "22887079"]]}], [{"prognostic_data": ["1", "Myeloproliferative Neoplasms", "LIQUID", "Myeloid", ["25516983", "22052707", "22887079"]]}], [{"prognostic_data": ["3", "Mature B-Cell Neoplasms", "LIQUID", "Lymphoid", ["8639789", "7579380", "28819011", "24684350", "26022239"]]}]]	chr17	7675153	GGGCGGGGGT	-
16	chr17	43082403	C	T			BRCA1	ENST00000357654.9	splice_site_variant	c.4357+1G>A		ENST00000352993.7:BRCA1:P38398:intron_variant,splice_site_variant::c.931+1G>A; ENST00000357654.9:BRCA1:P38398:intron_variant,splice_site_variant::c.4357+1G>A; ENST00000461221.5:BRCA1:P38398:intron_variant,NMD_transcript_variant,splice_site_variant::c.*4140+1G>A; ENST00000468300.5:BRCA1:P38398:intron_variant,splice_site_variant::c.1048+1G>A; ENST00000471181.7:BRCA1:P38398:intron_variant,splice_site_variant::c.4357+1G>A; ENST00000491747.6:BRCA1:P38398:intron_variant,splice_site_variant::c.1048+1G>A; ENST00000493795.5:BRCA1:P38398:intron_variant,splice_site_variant::c.4216+1G>A; ENST00000586385.5:BRCA1::intron_variant::c.5-18452G>A; ENST00000591534.5:BRCA1::intron_variant::c.-43-7882G>A; ENST00000591849.5:BRCA1::intron_variant::c.-98-32213G>A; ENST00000621897.1:BRCA1::intron_variant,processed_transcript::	1	s2		Likely Oncogenic	Likely Loss-of-function	False	1				11358863; 20608970; 12483515; 12947386	BRCA1, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.	The BRCA1 X1453_splice alteration is likely oncogenic.		[[{"treatment_data": [["C71721"], ["Olaparib"], ["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"], ["25366685", "30345884", "24882434"], 2, "Peritoneal Serous Carcinoma", "Peritoneum", "SOLID"]}], [{"treatment_data": [["C71721"], ["Olaparib"], ["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"], ["25366685", "30345884", "24882434"], 0, "", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C71721"], ["Olaparib"], ["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"], ["25366685", "30345884", "24882434"], 1, "Ovary/Fallopian Tube", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C71721"], ["Olaparib"], [], ["26510020", "32343890"], 0, "", "Prostate", "SOLID"]}], [{"treatment_data": [["C71721"], ["Olaparib"], [], ["26510020", "32343890"], 0, "", "Prostate", "SOLID"]}], [{"treatment_data": [["C71721", "C2039"], ["Olaparib", "Bevacizumab"], ["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"], ["25366685", "30345884", "24882434"], 2, "Peritoneal Serous Carcinoma", "Peritoneum", "SOLID"]}], [{"treatment_data": [["C71721", "C2039"], ["Olaparib", "Bevacizumab"], ["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"], ["25366685", "30345884", "24882434"], 0, "", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C71721", "C2039"], ["Olaparib", "Bevacizumab"], ["Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"], ["25366685", "30345884", "24882434"], 1, "Ovary/Fallopian Tube", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C137800"], ["Rucaparib"], [], [], 0, "", "Prostate", "SOLID"]}], [{"treatment_data": [["C137800"], ["Rucaparib"], [], [], 0, "", "Prostate", "SOLID"]}], [{"treatment_data": [["C137800"], ["Rucaparib"], ["Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."], ["28882436", "28916367", "32359490", "30425037"], 2, "Peritoneal Serous Carcinoma", "Peritoneum", "SOLID"]}], [{"treatment_data": [["C137800"], ["Rucaparib"], ["Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."], ["28882436", "28916367", "32359490", "30425037"], 0, "", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C137800"], ["Rucaparib"], ["Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."], ["28882436", "28916367", "32359490", "30425037"], 1, "Ovary/Fallopian Tube", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C80059"], ["Niraparib"], ["Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"], ["30948273", "27717299", "31562799"], 2, "Peritoneal Serous Carcinoma", "Peritoneum", "SOLID"]}], [{"treatment_data": [["C80059"], ["Niraparib"], ["Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"], ["30948273", "27717299", "31562799"], 0, "", "Ovary/Fallopian Tube", "SOLID"]}], [{"treatment_data": [["C80059"], ["Niraparib"], ["Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"], ["30948273", "27717299", "31562799"], 1, "Ovary/Fallopian Tube", "Ovary/Fallopian Tube", "SOLID"]}]]	chr17	43082403	C	T
#CRAVAT Report
#Created at Monday 12/20/2021 12:00:14
#Report level: gene
#
Variant Annotation					
Gene	Note	Number of Coding Variants	Number of Noncoding Variants	Sequence Ontology	All Sequence Ontologies
RET		1	0	start_lost	missense_variant(1),start_lost(1),NMD_transcript_variant(1)
GATA3		1	0	start_lost	missense_variant(1),start_lost(1)
PTEN		1	0	start_lost	missense_variant(1),start_lost(1),processed_transcript(1)
DDX20		1	0	missense_variant	missense_variant(1),NMD_transcript_variant(1),3_prime_UTR_variant(1),5_prime_UTR_variant(1)
CBL		1	0	start_lost	missense_variant(1),start_lost(1)
NPPA		1	0	start_lost	intron_variant(1),missense_variant(1),start_lost(1)
NOTCH2		1	0	start_lost	missense_variant(1),start_lost(1)
AADACL4		2	0	start_lost	missense_variant(2),start_lost(1)
APC		1	0	missense_variant	missense_variant(1),NMD_transcript_variant(1),3_prime_UTR_variant(1)
ABL1		1	0	missense_variant	missense_variant(1)
TP53		1	0	frameshift_truncation	frameshift_truncation(1),NMD_transcript_variant(1),processed_transcript(1),5_prime_UTR_variant(1)
BRCA1		0	1	splice_site_variant	intron_variant(1),NMD_transcript_variant(1),processed_transcript(1),splice_site_variant(1)
#CRAVAT Report
#Created at Monday 12/20/2021 12:00:14
#Report level: sample
#
Variant Annotation	
UID	Sample
1	s1
2	s2
3	s3
4	s4
5	s3
6	s4
7	s0
8	s0
9	s1
10	s2
11	s3
12	s4
13	s1
14	s0
15	s1
16	s2
#CRAVAT Report
#Created at Monday 12/20/2021 12:00:14
#Report level: mapping
#
Variant Annotation			
Original Line	User Tags	UID	Input File Number
1		1	0
2		2	0
3		3	0
4		4	0
5		5	0
6		6	0
7		7	0
8		8	0
9		9	0
10		10	0
11		11	0
12		12	0
13		13	0
14		14	0
15		15	0
16		16	0
